12 November2026: Biolojic Design receives FDA IND clearance for BD200, its first clinical-stage multibody
Biolojic Design has received U.S. FDA clearance of the IND application for BD200, an investigational multibody drug conjugate targeting TROP2 and Nectin-4, enabling initiation of a global Phase I study in patients with selected advanced solid tumors expressing these antigens. The company expects to begin the trial in the coming weeks
The first-in-human phase 1 trial will evaluate safety, tolerability, pharmacokinetics and preliminary antitumor activity. Following dose optimization, the study is expected to focus on selected tumor types and explore both monotherapy and combination treatment strategies
BD200 is designed to address tumor heterogeneity and acquired resistance associated with conventional single-target ADCs, where variable antigen expression and antigen-negative tumor cell populations can limit treatment response. By targeting two validated ADC antigens, the candidate aims to maintain tumor-cell recognition across different antigen-expression profiles
BD200 features a multibody architecture enabling each arm to independently bind TROP2 and/or Nectin-4, supporting dual-target or single-target engagement based on tumor antigen expression. It carries a potent topoisomerase I inhibitor payload via a proprietary linker designed to address tumor heterogeneity and potentially improve the therapeutic index
Strategically, BD200 introduces a differentiated ADC architecture that combines dual-antigen recognition with AI-driven antibody design, positioning Biolojic Design at the intersection of multispecific antibody engineering and next-generation ADC development. If clinical studies validate its preclinical potential, the multibody approach could offer an alternative strategy to address antigen heterogeneity and resistance beyond conventional monospecific and bispecific ADC formats